News

4-H Canada and Bayer Renew Five-Year Commitment to Invest in Youth through STEM

Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer

Bayer Fund shares over $100,000 in funding with students through its Opportunity Scholarship Program

European Society of Cardiology recommends (rivaroxaban) XARELTO® 2.5 mg plus acetylsalicylic acid for patients at high risk of heart attacks, strokes and death due to chronic coronary syndromes

Bayer completes sale of iconic Coppertone™ brand to Beiersdorf

Health Canada approves VITRAKVI® (larotrectinib), the first tumour agnostic cancer treatment for advanced solid tumours harbouring an NTRK gene fusion

Yellow Wood Partners to acquire iconic Dr. Scholl’s™ brand from Bayer